Inovio Pharmaceuticals, Inc. (NASDAQ:INO) Receives $44.00 Average PT from Brokerages

Shares of Inovio Pharmaceuticals, Inc. (NASDAQ:INO) have been given a consensus rating of “Moderate Buy” by the five ratings firms that are presently covering the stock, MarketBeat Ratings reports. Two research analysts have rated the stock with a hold rating and three have issued a buy rating on the company. The average twelve-month price objective among brokerages that have updated their coverage on the stock in the last year is $44.00.

Several research analysts have issued reports on INO shares. HC Wainwright reaffirmed a “neutral” rating and issued a $15.00 price target on shares of Inovio Pharmaceuticals in a report on Monday, July 15th. Oppenheimer dropped their target price on shares of Inovio Pharmaceuticals from $40.00 to $33.00 and set an “outperform” rating on the stock in a research report on Monday, August 12th. Finally, Royal Bank of Canada reduced their price objective on Inovio Pharmaceuticals from $11.00 to $8.00 and set a “sector perform” rating for the company in a research note on Friday, August 9th.

Hedge Funds Weigh In On Inovio Pharmaceuticals

Hedge funds have recently bought and sold shares of the business. The Manufacturers Life Insurance Company acquired a new position in Inovio Pharmaceuticals in the 2nd quarter valued at $82,000. Signature Estate & Investment Advisors LLC bought a new position in Inovio Pharmaceuticals in the second quarter worth $88,000. Cornercap Investment Counsel Inc. acquired a new stake in Inovio Pharmaceuticals during the second quarter worth $184,000. American Century Companies Inc. increased its holdings in Inovio Pharmaceuticals by 62.2% in the 2nd quarter. American Century Companies Inc. now owns 31,565 shares of the biopharmaceutical company’s stock valued at $255,000 after buying an additional 12,100 shares during the period. Finally, Rhumbline Advisers increased its holdings in Inovio Pharmaceuticals by 5,943.0% in the 2nd quarter. Rhumbline Advisers now owns 38,494 shares of the biopharmaceutical company’s stock valued at $311,000 after buying an additional 37,857 shares during the period. 26.79% of the stock is owned by institutional investors and hedge funds.

Inovio Pharmaceuticals Stock Down 1.4 %

INO stock opened at $5.78 on Friday. The firm’s 50-day simple moving average is $7.74 and its 200 day simple moving average is $9.56. Inovio Pharmaceuticals has a fifty-two week low of $3.89 and a fifty-two week high of $14.75.

Inovio Pharmaceuticals (NASDAQ:INO) last issued its quarterly earnings results on Thursday, August 8th. The biopharmaceutical company reported ($1.19) EPS for the quarter, missing analysts’ consensus estimates of ($1.10) by ($0.09). Inovio Pharmaceuticals had a negative net margin of 16,238.91% and a negative return on equity of 99.51%. The business had revenue of $0.10 million for the quarter, compared to analyst estimates of $0.10 million. During the same period last year, the business posted ($1.56) earnings per share. As a group, analysts forecast that Inovio Pharmaceuticals will post -4.64 EPS for the current fiscal year.

About Inovio Pharmaceuticals

Inovio Pharmaceuticals, Inc, a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids.